The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas

  title={The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas},
  author={Antonella di Sarno and Maria Luisa Landi and Paolo Marzullo and Carolina Di Somma and Rosario Pivonello and Gaetana Cerbone and Gaetano Lombardi and Annamaria Colao},
  journal={Clinical Endocrinology},
To compare effectiveness and tolerability of quinagolide (CV 205–502) and cabergoline (CAB) treatments in 39 patients with prolactinoma. 
Factors determining the remission of microprolactinomas after dopamine agonist withdrawal
Background  Withdrawal of dopamine agonist (DA) therapy in the management of microprolactinoma is common practice, but it is unclear which patients are likely to attain long‐term remission.
When can we stop cabergoline treatment in prolactinomas?
According to the authors' experience, they withdraw cabergoline treatment in prolactinomas after normalization of serum Prolactin levels and tumor disappearance or no further reduction of tumor size on MRI during the last 12 months of follow-up.
The great efficacy of CAB together with its excellent tolerability makes this drug the current treatment of choice for the majority of patients with hyperprolactinaemic disorders.
Management of resistant prolactinomas
Resistance to dopamine agonists occurs in a subset of patients with prolactin-secreting pituitary tumors, and the goal of therapy is to restore and maintain gonadal and neurologic function, and this might occur in the absence of a normal Prolactin level or a significant change in tumor size.
Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapy
Background  Remission rates of 76, 69·5 and 64·3% have been reported in patients with nontumoural hyperprolactinaemia (NTH), microprolactinoma and macroprolactinoma, respectively, 2–5 years after
Dopamine receptor agonists for treating prolactinomas
Notable tumour shrinkage until tumour disappearance was observed during cabergoline treatment in most patients with macroprolactinoma and it was also proven effective in patients resistant to or with a poor response to bromocriptine.
Clinical Pharmacokinetics of Cabergoline
The pharmacokinetic properties of cabergoline allow once daily administration in patients with Parkinsons’s disease and twice weekly administration in Patients with hyperprolactinaemia, making this drug advantageous over other dopaminergic agents in term of both therapeutic compliance and better symptom control.
Giant prolactinomas in men: efficacy of cabergoline treatment
Evaluating the efficacy and safety of CAB also for giant prolactinomas found Cabergoline, a long‐lasting dopamine agonist (DA), safe and well tolerated, is effective in normalizing PRL levels and inducing tumour shrinkage in micro‐ and macroprolactinoma.
Management of Dopamine Agonist-Resistant Prolactinoma
Any BRC-resistant patient should be switched to CAB which will normalize prolactin in 80% of patients, and dose escalation of CAB is reasonable, with the expectation that subsequent dose reduction will be possible.
Hyperprolactinemia and prolactinomas.


Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study
This work has investigated the biochemical efficacy and side-effect profile of a range of doses of the novel, long‐acting dopamine agonist, cabergoline, in suppressing prolactin (PRL) in hyperprolactinaemic women.
Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine
To audit the efficacy of quinagoiide in lowering prolactin, and its tolerability, in patients with bromocriptine resistance (BCR) or bromOCriptine intolerance (BCI), in view of the paucity of results published in patients specifically with BCR or BCI, by collating results in the patients with the reports in the literature.
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia, and may represent the only successful therapy for prolactinoma-bearing patients resistant to bromocriptine and quinagolide.
Growth-hormone and prolactin excess
Drugs five years later. Bromocriptine.
Withdrawal of bromocriptine therapy is associated in most patients with reversal of its beneficial effects--return of hyperprolactinemia, return of excess growth hormone secretion, and exacerbation of Parkinson's disease.
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
The data indicate that in at least half of such adenomas resistant to bromocriptine, CV 205-502, probably due to its higher affinity toward the D2 dopamine receptor, can overcome such resistance.
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients
This study indicates that, at the doses employed, cabergoline shows a better long-lasting efficacy and tolerability than quinagolide, and could be regarded as a further choice in the medical management of hyperprolactinemia.
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
It is indicated that cabergoline has potent and prolonged dopaminergic activity and may prove suitable for once weekly treatment of hyperprolactinemic patients.
Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas.
Since CV 205-502, administered in a single daily dose, has tolerable side-effects and is effective in reducing PRL secretion and tumor size, it can be considered to be a useful treatment for macroprolactinomas.
Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Long-term, a low dose of the D2 receptor agonist CAB significantly reduced tumor volume and normalized serum PRL levels in a great majority of patients bearing macroprolactinoma.